Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Gains from Investment Securities: 2024-2025

Historic Gains from Investment Securities for Kura Oncology (KURA) over the last 1 years, with Sep 2025 value amounting to $969,417.

  • Kura Oncology's Gains from Investment Securities was N/A to $969,417 in Q3 2025 from the same period last year, while for Sep 2025 it was $969,417, marking a year-over-year change of. This contributed to the annual value of $703,000 for FY2024, which is 151.07% up from last year.
  • As of Q3 2025, Kura Oncology's Gains from Investment Securities stood at $969,417, which was down 16.67% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Gains from Investment Securities registered a high of $1.2 million during Q1 2025, and its lowest value of $703,000 during Q4 2024.
  • Its 2-year average for Gains from Investment Securities is $999,754, with a median of $1.1 million in 2025.